The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease

Frontiers in Behavioral Neuroscience

Volumn , Issue JULY, 2012, Pages

  Vazey, Elena M ^a   Aston Jones, Gary ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Executive dysfunction; Locus coeruleus; Norepinephrine; Parkinson's disease

Indexed keywords

DOPAMINE; NORADRENALIN;

ARTICLE; CHOLINERGIC NERVE CELL; COGNITION; COGNITIVE DEFECT; COGNITIVE FLEXIBILITY; COGNITIVE INFLEXIBILITY; DOPAMINERGIC SYSTEM; HUMAN; LOCUS CERULEUS; MENTAL DISEASE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN INTERACTION;

EID: 84864390321     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2012.00048     Document Type: Article

References (95)

1. Aston-Jones, G., and Bloom, F.E. (1981). Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1, 876-886.
2. Aston-Jones, G., and Cohen, J.D. (2005). An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28, 403-450.
3. Aston-Jones, G., Rajkowski, J., Kubiak, P., Valentino, R.J., and Shipley, M.T. (1996). Role of the locus coeruleus in emotional activation. Prog Brain Res 107, 379-402.
4. Barone, P. (2010). Neurotransmission in Parkinson's disease: beyond dopamine. Eur J Neurol 17, 364-376.
5. Bedard, M.A., El Massioui, F., Malapani, C., Dubois, B., Pillon, B., Renault, B., and Agid, Y. (1998). Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clinical neuropharmacology 21, 108-117.
6. Berridge, C.W., and Abercrombie, E.D. (1999). Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis. Neuroscience 93, 1263-1270.
7. Berridge, C.W., and Waterhouse, B.D. (2003). The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42, 33-84.
8. Birrell, J.M., and Brown, V.J. (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20, 4320-4324.
9. Bohnen, N.I., Kaufer, D.I., Ivanco, L.S., Lopresti, B., Koeppe, R.A., Davis, J.G., Mathis, C.A., Moore, R.Y., and Dekosky, S.T. (2003). Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives of neurology 60, 1745-1748.
10. Bouret, S., and Sara, S.J. (2004). Reward expectation, orientation of attention and locus coeruleus-medial frontal cortex interplay during learning. Eur J Neurosci 20, 791-802.
11. Bouret, S., and Sara, S.J. (2005). Network reset: a simplified overarching theory of locus coeruleus noradrenaline function. Trends Neurosci 28, 574-582.
12. Braak, H., Del Tredici, K., Rub, U., De Vos, R.A., Jansen Steur, E.N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211.
13. Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., and Del Tredici, K. (2004). Stages in the development of Parkinson's disease-related pathology. Cell and tissue research 318, 121-134.
14. Braver, T.S., Paxton, J.L., Locke, H.S., and Barch, D.M. (2009). Flexible neural mechanisms of cognitive control within human prefrontal cortex. Proc Natl Acad Sci U S A 106, 7351-7356.
15. Calabresi, P., Picconi, B., Parnetti, L., and Di Filippo, M. (2006). A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. Lancet neurology 5, 974-983.
16. Carpentier, A.F., Bonnet, A.M., Vidailhet, M., and Agid, Y. (1996). Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 46, 1548-1551.
17. Chan-Palay, V., and Asan, E. (1989). Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287, 373-392.
18. Chudasama, Y., and Robbins, T.W. (2006). Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol 73, 19-38.
19. Clayton, E.C., Rajkowski, J., Cohen, J.D., and Aston-Jones, G. (2004). Phasic activation of monkey locus ceruleus neurons by simple decisions in a forced-choice task. J Neurosci 24, 9914-9920.
20. Collins, P., Wilkinson, L.S., Everitt, B.J., Robbins, T.W., and Roberts, A.C. (2000). The effect of dopamine depletion from the caudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function. Behav Neurosci 114, 3-17.
21. Corbetta, M., Patel, G., and Shulman, G.L. (2008). The reorienting system of the human brain: from environment to theory of mind. Neuron 58, 306-324.
22. Crofts, H.S., Dalley, J.W., Collins, P., Van Denderen, J.C., Everitt, B.J., Robbins, T.W., and Roberts, A.C. (2001). Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb Cortex 11, 1015-1026.
23. Dayan, P., and Yu, A.J. (2006). Phasic norepinephrine: a neural interrupt signal for unexpected events. Network 17, 335-350.
24. Diaz, N.L., and Waters, C.H. (2009). Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev Neurother 9, 1781-1789.
25. Dickson, D.W., Braak, H., Duda, J.E., Duyckaerts, C., Gasser, T., Halliday, G.M., Hardy, J., Leverenz, J.B., Del Tredici, K., Wszolek, Z.K., and Litvan, I. (2009). Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet neurology 8, 1150-1157.
26. Downes, J.J., Roberts, A.C., Sahakian, B.J., Evenden, J.L., Morris, R.G., and Robbins, T.W. (1989). Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 27, 1329-1343.
27. Ehrt, U., Broich, K., Larsen, J.P., Ballard, C., and Aarsland, D. (2010). Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. Journal of neurology, neurosurgery, and psychiatry 81, 160-165.
28. Espana, R.A., and Berridge, C.W. (2006). Organization of noradrenergic efferents to arousal-related basal forebrain structures. The Journal of comparative neurology 496, 668-683.
29. Floresco, S.B., Block, A.E., and Tse, M.T. (2008). Inactivation of the medial prefrontal cortex of the rat impairs strategy set-shifting, but not reversal learning, using a novel, automated procedure. Behav Brain Res 190, 85-96.
30. Floresco, S.B., and Jentsch, J.D. (2011). Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology 36, 227-250.
31. Floresco, S.B., Magyar, O., Ghods-Sharifi, S., Vexelman, C., and Tse, M.T. (2006). Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 31, 297-309.
32. Floresco, S.B., Zhang, Y., and Enomoto, T. (2009). Neural circuits subserving behavioral flexibility and their relevance to schizophrenia. Behav Brain Res 204, 396-409.
33. Florin-Lechner, S.M., Druhan, J.P., Aston-Jones, G., and Valentino, R.J. (1996). Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res 742, 89-97.
34. Foote, S.L., Bloom, F.E., and Aston-Jones, G. (1983). Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63, 844-914.
35. Fornai, F., Di Poggio, A.B., Pellegrini, A., Ruggieri, S., and Paparelli, A. (2007). Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 14, 2330-2334.
36. Fulceri, F., Biagioni, F., Ferrucci, M., Lazzeri, G., Bartalucci, A., Galli, V., Ruggieri, S., Paparelli, A., and Fornai, F. (2007). Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res 1135, 219-229.
37. German, D.C., Manaye, K.F., White, C.L., 3rd, Woodward, D.J., Mcintire, D.D., Smith, W.K., Kalaria, R.N., and Mann, D.M. (1992). Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32, 667-676.
38. Gesi, M., Soldani, P., Giorgi, F.S., Santinami, A., Bonaccorsi, I., and Fornai, F. (2000). The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 24, 655-668.
39. Goldstein, D.S., Sullivan, P., Holmes, C., Kopin, I.J., Basile, M.J., and Mash, D.C. (2011). Catechols in post-mortem brain of patients with Parkinson disease. European journal of neurology: the official journal of the European Federation of Neurological Societies 18, 703-710.
40. Gonzalez, M.M., and Aston-Jones, G. (2008). Light deprivation damages monoamine neurons and produces a depressive behavioral phenotype in rats. Proc Natl Acad Sci U S A 105, 4898-4903.
41. Green, J., Mcdonald, W.M., Vitek, J.L., Evatt, M., Freeman, A., Haber, M., Bakay, R.A., Triche, S., Sirockman, B., and Delong, M.R. (2002). Cognitive impairments in advanced PD without dementia. Neurology 59, 1320-1324.
42. Halliday, G., Hely, M., Reid, W., and Morris, J. (2008). The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta neuropathologica 115, 409-415.
43. Halliday, G.M., Del Tredici, K., and Braak, H. (2006). Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl, 99-103.
44. Hawkes, C.H. (2008). The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Movement disorders: official journal of the Movement Disorder Society 23, 1799-1807.
45. Hawkes, C.H., Del Tredici, K., and Braak, H. (2010). A timeline for Parkinson's disease. Parkinsonism & relateddisorders 16, 79-84.
46. Heneka, M.T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jardanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U.K., and Kummer, M.P. (2010). Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A 107, 6058-6063.
47. Hilker, R., Thomas, A.V., Klein, J.C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A.H., Herholz, K., and Heiss, W.D. (2005). Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65, 1716-1722.
48. Hirsch, E., Graybiel, A.M., and Agid, Y.A. (1988). Melanized dopaminergic neurons are differentially susceptible todegeneration in Parkinson's disease. Nature 334, 345-348.
49. Hoehn, M.M., and Yahr, M.D. (1967). Parkinsonism: onset, progression and mortality. Neurology 17, 427-442.
50. Jankovic, J. (2009). Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci 284, 177-178.
51. Jellinger, K.A. (2006). The morphological basis of mental dysfunction in Parkinson's disease. Journal of the neurological sciences 248, 167-172.
52. Jones, B.E. (2004). Activity, modulation and role of basal forebrain cholinergic neurons innervating the cerebral cortex. Progress in brain research 145, 157-169.
53. Jubault, T., Monetta, L., Strafella, A.P., Lafontaine, A.L., and Monchi, O. (2009). L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network. PLoS One 4, e6154.
54. Kehagia, A.A., Barker, R.A., and Robbins, T.W. (2010a). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 9, 1200-1213.
55. Kehagia, A.A., Murray, G.K., and Robbins, T.W. (2010b). Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol 20, 199-204.
56. Keri, S., Moustafa, A.A., Myers, C.E., Benedek, G., and Gluck, M.A. (2010). α-Synuclein gene duplication impairs reward learning. Proc Natl Acad Sci U S A 107, 15992-15994.
57. Konishi, S., Kawazu, M., Uchida, I., Kikyo, H., Asakura, I., and Miyashita, Y. (1999). Contribution of working memory to transient activation in human inferior prefrontal cortex during performance of the Wisconsin Card Sorting Test. Cereb Cortex 9, 745-753.
58. Lange, K.W., Robbins, T.W., Marsden, C.D., James, M., Owen, A.M., and Paul, G.M. (1992). L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 107, 394-404.
59. Lapiz, M.D., Bondi, C.O., and Morilak, D.A. (2007). Chronic treatment with desipramine improves cognitive performance of rats in an attentional set-shifting test. Neuropsychopharmacology 32, 1000-1010.
60. Lapiz, M.D., and Morilak, D.A. (2006). Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability. Neuroscience 137, 1039-1049.
61. Lees, A.J., and Smith, E. (1983). Cognitive deficits in the early stages of Parkinson's disease. Brain 106 (Pt 2), 257-270.
62. Leverenz, J.B., Quinn, J.F., Zabetian, C., Zhang, J., Montine, K.S., and Montine, T.J. (2009). Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem 9, 903-912.
63. Litvan, I., Bhatia, K.P., Burn, D.J., Goetz, C.G., Lang, A.E., Mckeith, I., Quinn, N., Sethi, K.D., Shults, C., and Wenning, G.K. (2003). Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Movement disorders: official journal of the Movement Disorder Society 18, 467-486.
64. Maingay, M., Romero-Ramos, M., Carta, M., and Kirik, D. (2006). Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of disease 23, 522-532.
65. Marsh, L., Biglan, K., Gerstenhaber, M., and Williams, J.R. (2009). Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 24, 277-282.
66. Mavridis, M., Degryse, A.D., Lategan, A.J., Marien, M.R., and Colpaert, F.C. (1991). Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41, 507-523.
67. Mcgaughy, J., Ross, R.S., and Eichenbaum, H. (2008). Noradrenergic, but not cholinergic, deafferentation of prefrontal cortex impairs attentional set-shifting. Neuroscience 153, 63-71.
68. Miller, E.K., and Cohen, J.D. (2001). An integrative theory of prefrontal cortex function. Annu Rev Neurosci 24, 167-202.
69. Monchi, O., Petrides, M., Doyon, J., Postuma, R.B., Worsley, K., and Dagher, A. (2004). Neural bases of set-shifting deficits in Parkinson's disease. J Neurosci 24, 702-710.
70. Nagano-Saito, A., Leyton, M., Monchi, O., Goldberg, Y.K., He, Y., and Dagher, A. (2008). Dopamine depletion impairs frontostriatal functional connectivity during a set-shifting task. J Neurosci 28, 3697-3706.
71. Nayyar, T., Bubser, M., Ferguson, M.C., Neely, M.D., Shawn Goodwin, J., Montine, T.J., Deutch, A.Y., and Ansah, T.A. (2009). Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation. The European journal of neuroscience 30, 207-216.
72. Newman, L.A., Darling, J., and Mcgaughy, J. (2008). Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl) 200, 39-50.
73. Owen, A.M., James, M., Leigh, P.N., Summers, B.A., Marsden, C.D., Quinn, N.P., Lange, K.W., and Robbins, T.W. (1992). Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 115 (Pt 6), 1727-1751.
74. Owen, A.M., Roberts, A.C., Hodges, J.R., Summers, B.A., Polkey, C.E., and Robbins, T.W. (1993). Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 116 (Pt 5), 1159-1175.
75. Petrovitch, H., Abbott, R., Ross, W., Uyehara-Lock, J., and White, L. (2011). Poor Executive Function, Neuron Loss, and Gliosis in the Locus Coeruleus: The Honolulu-Asia Aging Study. American Academy of Neurology Annual Meeting Honolulu, HI.
76. Pintor, L., Bailles, E., Valldeoriola, F., Tolosa, E., Marti, M.J., and De Pablo, J. (2006). Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. General hospital psychiatry 28, 59-64.
77. Ragozzino, M.E. (2002). The effects of dopamine D(1) receptor blockade in the prelimbic-infralimbic areas on behavioral flexibility. Learn Mem 9, 18-28.
78. Rascol, O., Arnulf, I., Peyro-Saint Paul, H., Brefel-Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A.M., Descombes, S., Bejjani, B., Fabre, N., Montastruc, J.L., and Agid, Y. (2001). Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 16, 708-713.
79. Robbins, T.W., and Arnsten, A.F. (2009). The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32, 267-287.
80. Robbins, T.W., and Roberts, A.C. (2007). Differential regulation of fronto-executive function by the monoamines and acetylcholine. Cereb Cortex 17 Suppl 1, i151-160.
81. Roberts, A.C., De Salvia, M.A., Wilkinson, L.S., Collins, P., Muir, J.L., Everitt, B.J., and Robbins, T.W. (1994). 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 14, 2531-2544.
82. Rodriguez-Ferreiro, J., Cuetos, F., Herrera, E., Menendez, M., and Ribacoba, R. (2010). Cognitive impairment in Parkinson's disease without dementia. Mov Disord 25, 2136-2141.
83. Rommelfanger, K.S., Edwards, G.L., Freeman, K.G., Liles, L.C., Miller, G.W., and Weinshenker, D. (2007). Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A 104, 13804-13809.
84. Rommelfanger, K.S., and Weinshenker, D. (2007). Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochemical pharmacology 74, 177-190.
85. Servan-Schreiber, D., Printz, H., and Cohen, J.D. (1990). A network model of catecholamine effects: gain, signal-to-noise ratio, and behavior. Science 249, 892-895.
86. Srinivasan, J., and Schmidt, W.J. (2003). Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci 17, 2586-2592.
87. Tait, D.S., Brown, V.J., Farovik, A., Theobald, D.E., Dalley, J.W., and Robbins, T.W. (2007). Lesions of the dorsal noradrenergic bundle impair attentional set-shifting in the rat. Eur J Neurosci 25, 3719-3724.
88. Usher, M., Cohen, J.D., Servan-Schreiber, D., Rajkowski, J., and Aston-Jones, G. (1999). The role of locus coeruleus in the regulation of cognitive performance. Science 283, 549-554.
89. Waterhouse, B.D., Devilbiss, D., Fleischer, D., Sessler, F.M., and Simpson, K.L. (1998). New perspectives on the functional organization and postsynaptic influences of the locus ceruleus efferent projection system. Adv Pharmacol 42, 749-754.
90. Weinshenker, D. (2008). Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res 5, 342-345.
91. Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A.D., Duda, J.E., Hurtig, H.I., Colcher, A., Horn, S.S., Nazem, S., Ten Have, T.R., and Stern, M.B. (2010). Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75, 448-455.
92. Williams-Gray, C.H., Foltynie, T., Brayne, C.E., Robbins, T.W., and Barker, R.A. (2007). Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain: a journal of neurology 130, 1787-1798.
93. Wolters, E. (2009). Non-motor extranigral signs and symptoms in Parkinson's disease. Parkinsonism Relat Disord 15 Suppl 3, S6-12.
94. Woodward, D.J., Moises, H.C., Waterhouse, B.D., Hoffer, B.J., and Freedman, R. (1979). Modulatory actions of norepinephrine in the central nervous system. Fed Proc 38, 2109-2116.
95. Zweig, R.M., Cardillo, J.E., Cohen, M., Giere, S., and Hedreen, J.C. (1993). The locus ceruleus and dementia in Parkinson's disease. Neurology 43, 986-991.